Insider

Johnson & Johnson receives market authorization for OTTAVA and new oncology and hematology drugs

On October 13, 2026, Johnson & Johnson announced market authorization of the OTTAVA system – the world’s first robotic device integrated into an operating table – approval of IMAAVY for warm autoimmune hemolytic anemia (wAIHA) and the start of priority review for RYBREVANT FASPRO for advanced head and neck cancer. The moves expand the company’s portfolio in robotic surgery, hematology and oncology.

Verified against 1 archived primary source · SHA-256 recorded Inspect sources & citations ↓
gray surgical scissors near doctors in operating room
Photo by Piron Guillaume on Unsplash

Key points

  • The company announced market authorization for OTTAVA, approval of IMAAVY in wAIHA and priority review of RYBREVANT FASPRO for advanced head and neck cancer.
  • The drug IMAAVY is aimed at patients with warm autoimmune hemolytic anemia, and RYBREVANT FASPRO is for people with advanced head and neck tumors.
  • The FDA granted market authorization for OTTAVA, approved IMAAVY and gave priority review to RYBREVANT FASPRO.

What happened

The company announced market authorization for OTTAVA, approval of IMAAVY in wAIHA and priority review of RYBREVANT FASPRO for advanced head and neck cancer.

Who it matters to

The drug IMAAVY is aimed at patients with warm autoimmune hemolytic anemia, and RYBREVANT FASPRO is for people with advanced head and neck tumors.

Evidence

The FDA granted market authorization for OTTAVA, approved IMAAVY and gave priority review to RYBREVANT FASPRO.

Next step

The FDA will continue priority review of RYBREVANT FASPRO; a final decision date was not provided.

Original sources

  1. 8-K EX-99.1 filing, October 13, 2026October 13, 2026SHA-256 of our archived copy 9d63f1981827…
Cite this article

The fingerprint identifies the exact version of each original that the article was written from; the original stays at its source.

Prepared by AI from official company documents; automatic checks and an AI editor review it before publication, and not every article is read by a person. This is not investment advice. Editorial standards